Navigation Links
Sally L. Glaser, Ph.D., Named CEO of the Northern California Cancer Center
Date:4/14/2009

Specialist in Hodgkin lymphoma to lead cancer prevention efforts at one of the nation's largest prevention-focused cancer research centers

FREMONT, Calif., April 14 /PRNewswire-USNewswire/ -- Sally L. Glaser, Ph.D., a 19-year veteran at the Northern California Cancer Center (NCCC), has been promoted to Chief Executive Officer of the organization, which is the only center in the country conducting research dedicated solely to cancer prevention. NCCC employs 135 staff members and has a $14 million operating budget. Dr. Glaser, a research scientist, will continue to direct NCCC's Greater Bay Area Cancer Registry, which collects cancer data for its nine-county catchment area to better understand patterns of cancer occurrence, treatment and survival. Previously, Dr. Glaser served as Director of Surveillance Research at NCCC. She earned an A.B. from Harvard University and an M.S. and Ph.D. in Epidemiology from the University of California, Berkeley.

"NCCC is positioned to be a critical partner in America's revitalized effort to eradicate cancer," said Dr. Glaser, "I'm excited to lead our professional team of researchers and numerous other staff members at the forefront of that mission at NCCC."

NCCC is a nationally recognized leader in researching the causes of cancer and improving cancer detection and prevention. The organization's programs, while multifaceted, all address the inter-related aspects of cancer prevention. Programs include the cancer registry, which tracks all cases for two of California's ten cancer-reporting regions and aids NCCC in determining the size of the problem of cancer occurrences and death. The organization also conducts a wide variety of research studies, using data from the registry and other sources to determine the causes of cancer and factors related to survival after cancer. NCCC's distinctive outreach and community education programs actively bring cancer prevention services to underserved and low-income communities and improve the quality of life for individuals living with cancer. NCCC's programs are also integral to the organization's partnership with Stanford University and contribute to the university's National Cancer Institute Cancer Center designation.

"We're extremely happy to have Dr. Glaser as CEO," said NCCC Chairman of the Board Samuel Bronfman II. "Her scientific merits and experience combined with her vision, enthusiasm, and ability to motivate others make her a perfect choice for this position." Bronfman cited Dr. Glaser's research expertise, management skills and passion for the work of NCCC scientists, registry staff, and community educators, saying it has been "an asset to her leadership thus far and will continue to inspire support for the cancer prevention cause."

The research that comes out of NCCC builds upon established knowledge bases worldwide and contributes to the deepening understanding of how cancer affects the entire population rather than only the individual patient. The organization also examines what can be done to stop the spread of the disease. NCCC works closely with regional, state, and national health departments concerned with policy and health practice interventions in order to maximize the health of individuals and families.

"Cancer surveillance is like an early warning system for the many diseases we call 'cancer,'" said Dr. Glaser. "It tells us what's happening in the Greater Bay Area and in the state -- not just in individual clinics. And while not all cancer can yet be prevented, there is much more we can do to strengthen California's response." Addressing areas in which NCCC will play a leading role, Dr. Glaser cited ongoing research into the emerging causes of cancers, community outreach, education efforts, and programs that promote screenings for early detection when most cancers can easily be treated. The organization is committed to conducting new research studies that point to interventions that can stop cancer before it starts, and continues its leadership in state outreach programs for low-income women.

About the Northern California Cancer Center:

Based in the San Francisco Bay Area city of Fremont, the Northern California Cancer Center (NCCC) is an independent 501 (c) (3) non-profit organization with a $14 million operating budget. It devotes its research efforts to understanding who gets cancer and why, leading to more effective prevention. NCCC was founded in 1974 by a consortium of the Stanford University and University of California San Francisco medical schools, the California chapter of the American Cancer Society, and community leaders. In 35 years of operation, it has grown from its original role of assisting with clinical trials of cancer drugs to serving as an asset to the nation's leading cancer fighting organizations, including the National Institutes of Health and the National Cancer Institute, scientists worldwide, educators, patients, and clinicians. For more information, visit the Northern California Cancer Center's website at www.nccc.org.


'/>"/>
SOURCE Northern California Cancer Center
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sally W. Crawford Joins Insulets Board of Directors
2. Sally Jessy Raphael Bids Farewell to Her Infamous Red Glasses, Reports Green Nest
3. Mount Sinai researchers discover novel mechanisms that might causally link type-2 diabetes to Alzheimers disease
4. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
5. Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
6. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
7. ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
8. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
9. Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors
10. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
11. BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), ... labor and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding ... the hospital and decide to donate. , “Women’s Hospital at Renaissance has been ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... of ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled ... wearable activity and sleep monitoring solutions for the global scientific community. The company’s ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
Breaking Medicine Technology: